Prasterone (DHEA) for Metastatic or Unresectable Synovial Sarcoma
Researchers have studied prasterone—also known as DHEA (dehydroepiandrosterone)—as a potential treatment option for people with synovial sarcoma that has spread (metastatic) or cannot be removed through surgery. This clinical study was designed to better understand the safety of prasterone, determine appropriate dosing, and explore whether it could help slow or control disease progression. This trial is now closed and is no longer enrolling or treating patients.
Why Prasterone?
Prasterone is a hormone-related compound that researchers believed might interfere with tumor growth by affecting enzymes involved in cell metabolism and growth. This made it of interest as a possible therapeutic approach for synovial sarcoma.
What The Study Aimed To Learn
This research was conducted as a Phase I/II clinical trial.
In Phase I, the goal was to identify the maximum tolerated dose of prasterone in people with synovial sarcoma. In Phase II, researchers evaluated how many patients experienced disease stability or response while receiving that dose.
Additional objectives included monitoring progression-free survival, understanding side effects and safety over time, and exploring biological markers that might help explain how patients responded to treatment.
What Participation Involved
Participants took prasterone orally once a day in repeating 28-day cycles, continuing treatment as long as the cancer did not worsen and side effects remained manageable. After completing treatment, patients were followed over time to monitor long-term outcomes.
Who The Study Was Designed For
The trial focused on individuals diagnosed with metastatic or unresectable synovial sarcoma who had already received at least one prior line of chemotherapy. Participants were required to have measurable disease on imaging and meet specific health and safety criteria. Certain medical conditions and medications excluded participation to ensure patient safety.
Why This Research Still Matters
Although this particular trial is no longer active, it represents an important step in exploring new therapeutic approaches for synovial sarcoma. Each study contributes to a growing body of knowledge that helps inform future research, clinical trials, and treatment strategies.
For patients and families navigating synovial sarcoma today, discussing clinical trial options with a sarcoma specialist and staying informed about emerging research may help open doors to new possibilities.
For more detailed information, please refer to the original article.For more detailed information about Synovial Sarcoma resources and support, please visit our website.
